For research use only. Not for therapeutic Use.
Pirodavir（Cat No.:I000970）is an antiviral compound primarily studied for its potential to combat rhinovirus infections, the leading cause of the common cold. It functions by inhibiting viral replication through interaction with the viral capsid, preventing the virus from attaching to and penetrating host cells. Pirodavir demonstrates activity against a broad spectrum of rhinovirus serotypes, making it a promising candidate for respiratory virus research. Its high specificity and efficacy in vitro have spurred interest in its use for therapeutic development, particularly in addressing respiratory tract infections caused by picornaviruses.
| Catalog Number | I000970 |
| CAS Number | 124436-59-5 |
| Synonyms | R 77975 |
| Molecular Formula | C21H27N3O3 |
| Purity | ≥95% |
| Target | Enterovirus |
| Solubility | DMSO 67 mg/mL; Water <1 mg/mL; Ethanol 7 mg/mL |
| Storage | -20°C |
| IC50 | Pirodavir inhibits 80 percentage of viruses at 0.064 micrograms/ml(EC80)[2]. |
| IUPAC Name | ethyl 4-[2-[1-(6-methylpyridazin-3-yl)piperidin-4-yl]ethoxy]benzoate |
| InChI | InChI=1S/C21H27N3O3/c1-3-26-21(25)18-5-7-19(8-6-18)27-15-12-17-10-13-24(14-11-17)20-9-4-16(2)22-23-20/h4-9,17H,3,10-15H2,1-2H3 |
| InChIKey | KCHIOGFOPPOUJC-UHFFFAOYSA-N |
| SMILES | CCOC(=O)C1=CC=C(C=C1)OCCC2CCN(CC2)C3=NN=C(C=C3)C |
| Reference | </br>1:In vitro characterisation of a pleconaril/pirodavir-like compound with potent activity against rhinoviruses. Lacroix C, Laconi S, Angius F, Coluccia A, Silvestri R, Pompei R, Neyts J, Leyssen P.Virol J. 2015 Jul 14;12:106. doi: 10.1186/s12985-015-0330-4. PMID: 26169596 Free PMC Article</br>2:Exploration of the anti-enterovirus activity of a series of pleconaril/pirodavir-like compounds. Bernard A, Lacroix C, Cabiddu MG, Neyts J, Leyssen P, Pompei R.Antivir Chem Chemother. 2015 Apr;24(2):56-61. doi: 10.1177/2040206615589035. Epub 2015 Jun 11. PMID: 26071135 </br>3:In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity. Barnard DL, Hubbard VD, Smee DF, Sidwell RW, Watson KG, Tucker SP, Reece PA.Antimicrob Agents Chemother. 2004 May;48(5):1766-72. PMID: 15105133 Free PMC Article</br>4:Stabilisation of poliovirus with pirodavir. Rombaut B, Andries K, Boeyé A.Dev Biol Stand. 1996;87:173-80. PMID: 8854015 </br>5:Intranasal pirodavir (R77,975) treatment of rhinovirus colds. Hayden FG, Hipskind GJ, Woerner DH, Eisen GF, Janssens M, Janssen PA, Andries K.Antimicrob Agents Chemother. 1995 Feb;39(2):290-4. PMID: 7726484 Free PMC Article</br>6:Safety and efficacy of intranasal pirodavir (R77975) in experimental rhinovirus infection. Hayden FG, Andries K, Janssen PA.Antimicrob Agents Chemother. 1992 Apr;36(4):727-32. PMID: 1503435 Free PMC Article</br>7:In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity. Andries K, Dewindt B, Snoeks J, Willebrords R, van Eemeren K, Stokbroekx R, Janssen PA.Antimicrob Agents Chemother. 1992 Jan;36(1):100-7. PMID: 1317142 Free PMC Article |
